Skip to content

Development of a Novel Screening Tool for Anosognosia After Stroke.

Development and Exploration of the Acceptability and Feasibility of a Novel Screening Tool for Anosognosia After Stroke, Designed for Routine Use in Hospital Settings.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06940882
Enrollment
90
Registered
2025-04-23
Start date
2025-10-31
Completion date
2026-06-30
Last updated
2025-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anosognosia, Stroke

Keywords

Anosognosia, Stroke, Assessment

Brief summary

Anosognosia, a neurological inability to acknowledge or comprehend one's own (dis)abilities, is a multi-faceted phenomenon which has consistently gained traction in research fields spanning psychology, neurology, and cognition since its conceptual introduction in 1914. Though anosognosia is not limited to following only neurological disease or injury, the majority of research has focused on the prevalence and mechanisms of anosognosia after stroke. Despite this, there is no clear consensus among the literature, and thus in clinical practice, as to how anosognosia after stroke should be assessed. This is startling given the plethora of studies which highlight anosognosia as a barrier to rehabilitation, a risk to safe discharge, and a predictor of poorer psychological and functional outcomes for both patients and their carers. Currently, there exists a vast number of assessment methods for anosognosia after stroke, which vary from performance- and observation-based tasks to self-report and discrepancy-based interviews; clinicians working in stroke make arbitrary choices as to which of these methods to use on a case-by-case basis, risking missed cases and subsequently noncomprehensive care. This research aims to develop a new screening tool for anosognosia that can be routinely implemented with post-stroke patients in hospital settings, to inform care, rehabilitation, and discharge. The study will explore the acceptability and feasibility of the new screening tool among multi-disciplinary staff working on a stroke rehabilitation unit, and provide grounds for future studies to assess the screen's psychometric properties and ability to inform novel interventions for anosognosia. Findings will have great implications for stroke survivors, their carers, and healthcare professionals alike.

Interventions

None listed

Sponsors

Royal Devon and Exeter NHS Foundation Trust
CollaboratorOTHER
University of Exeter
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years or above who are admitted to the stroke rehabilitation unit with a clinical diagnosis of stroke. * Multi-disciplinary staff working on the stroke rehabilitation unit.

Exclusion criteria

* Patients with a clinical diagnosis other than stroke.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability and Feasibility of new screening tool among multi-disciplinary staffFrom recruitment, throughout 4-6 months of screen implementation, to the completion of focus groups approximately 8 months after recruitment.Focus groups will be conducted with staff who administer the new screening tool on the target stroke rehabilitation ward, to explore their views of and experiences with the tool. This will be in relation to the tool's content, structure, length, response/scoring formats, and administration demands.

Secondary

MeasureTime frameDescription
Uptake and Validity of new screening tool, with patientsOver 4-6 months, from recruitment until the completion of screen implementation.Demographic data and stroke-related data (stroke location, severity) will provide descriptive insight into the usability of the tool across subgroups of the sample. Numbers of completed forms will provide descriptive insight into the uptake of the screening tool. Inter-rater reliability will provide insight into the tool's equivalence.

Contacts

Primary ContactGeorgia M Williams, In Completion of DClinPsy
gw537@exeter.ac.uk+447907685213
Backup ContactAlexis Clarke, DClinPsy, QiCN
alexis.clarke8@exeter.ac.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026